Anzeige
Mehr »
Login
Mittwoch, 25.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Während die Wall Street über Krypto-ETFs debattiert, liefert dieses Unternehmen 1.000?% RENDITE!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

AFX News-Archiv vom 17.11.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
17.11.Japan Core Machinery Order Data Due On Monday297HONG KONG (dpa-AFX) - Japan will on Monday release September figures for core machine orders, highlighting a modest day for Asia-Pacific economic activity. In August, orders were down 1.9 percent...
► Artikel lesen
17.11.Alnylam Presents New Phase 1 Results For Next-Gen RNAi Therapy Nucresiran In ATTR Amyloidosis536WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) has shared new findings from its Phase 1 study of nucresiran (previously known as ALN-TTRsc04), a next-generation RNAi therapy being...
► Artikel lesen
17.11.Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management748FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% of participants with...
► Artikel lesen
17.11.BSX: WATCHMAN FLX Device Reduces Bleeding Risk, Matches Stroke Prevention After Cardiac Ablation660WASHINGTON (dpa-AFX) - Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrirl Appendage Closure...
► Artikel lesen
17.11.BioMarin: Real-World Evidence Supports Safety, Efficacy Of VOXZOGO In Children With Achondroplasia622WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced positive and consistent results from multiple real-world evidence studies of VOXZOGO (vosoritide) in children with achondroplasia....
► Artikel lesen
17.11.Lilly' Tirzepatide Reduces Heart Failure Risk, Improves Symptoms In HFpEF Patients With Obesity574INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly lowered the risk of worsening heart...
► Artikel lesen